



Supplementary Figure 4. Plasma chemokine and cytokine modulation during ofatumumab and lenalidomide treatment. CCL2 (A), CCL3 (B), CCL4 (C), TNF α (D), IFN α 2 (E), and IL-12p70 (F) plasma levels were measured before the treatment and at the beginning of course 3. Dots represent concentrations at course 3 as a percentage of the baseline level for each patient. Mean \pm SEM for each group of patients is shown. Non responders (NR) show increased chemokine/cytokine levels following therapy as compared to partial responders (PR) or complete responders (CR). *p<0.05; **p<0.01.